Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
150 hedge funds and large institutions have $311M invested in Progenics Pharmaceuticals Inc in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 48 reducing their positions, and 23 closing their positions.
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
1% more funds holding
Funds holding: 148 → 150 (+2)
2% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 48
1% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $4.46M
37% less capital invested
Capital invested by funds: $490M → $311M (-$179M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.3M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$2.99M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$2.94M |
| 4 |
Millennium Management
New York
|
+$2.8M |
| 5 |
Citigroup
New York
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.02M |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$7.73M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.58M |
PGNX Hedge Fund Activity: Q4 2018 in Review
150 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2018, worth a combined $311M — down 37% from $490M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PGNX positions and 23 closed out — a net gain of 3 holders — while 49 added to existing stakes and 48 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $24.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $19M sold.
- 150 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2018, up from 148 in Q3 2018.
- Funds reported $311M of Progenics Pharmaceuticals Inc stock for Q4 2018, down 37% quarter-over-quarter.
- 26 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2018 and 23 closed out, a net change of +3 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $24.3M added.
- The largest Progenics Pharmaceuticals Inc seller in Q4 2018 was RA Capital Management, an estimated $19M sold.
Based on aggregated 13F filings for Q4 2018.